DK4324522T3 - Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion - Google Patents

Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion

Info

Publication number
DK4324522T3
DK4324522T3 DK23219949.7T DK23219949T DK4324522T3 DK 4324522 T3 DK4324522 T3 DK 4324522T3 DK 23219949 T DK23219949 T DK 23219949T DK 4324522 T3 DK4324522 T3 DK 4324522T3
Authority
DK
Denmark
Prior art keywords
methods
renal function
impaired renal
fabry patients
treating fabry
Prior art date
Application number
DK23219949.7T
Other languages
English (en)
Inventor
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4324522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK4324522T3 publication Critical patent/DK4324522T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK23219949.7T 2017-05-30 2018-05-30 Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion DK4324522T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512458P 2017-05-30 2017-05-30
US201862626953P 2018-02-06 2018-02-06
EP23189734.9A EP4245366A3 (en) 2017-05-30 2018-05-30 Migalastat for treating fabry patients having renal impairment

Publications (1)

Publication Number Publication Date
DK4324522T3 true DK4324522T3 (da) 2026-03-16

Family

ID=65803261

Family Applications (4)

Application Number Title Priority Date Filing Date
DK23219933.1T DK4327869T3 (da) 2017-05-30 2018-05-30 Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion
DK18733415.6T DK3630114T3 (da) 2017-05-30 2018-05-30 Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion
DK22165669.7T DK4062916T3 (da) 2017-05-30 2018-05-30 Behandling af fabry-patienter med specifikke mutationer
DK23219949.7T DK4324522T3 (da) 2017-05-30 2018-05-30 Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK23219933.1T DK4327869T3 (da) 2017-05-30 2018-05-30 Fremgangsmåder til behandling af fabry-patienter med nedsat nyrefunktion
DK18733415.6T DK3630114T3 (da) 2017-05-30 2018-05-30 Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion
DK22165669.7T DK4062916T3 (da) 2017-05-30 2018-05-30 Behandling af fabry-patienter med specifikke mutationer

Country Status (14)

Country Link
EP (9) EP4245366A3 (da)
CN (4) CN117357524A (da)
DK (4) DK4327869T3 (da)
ES (5) ES3002433T3 (da)
FI (4) FI4327869T3 (da)
HR (4) HRP20240061T1 (da)
HU (2) HUE069837T2 (da)
LT (4) LT4324522T (da)
PL (4) PL3630114T3 (da)
PT (4) PT4324522T (da)
RS (4) RS65230B1 (da)
SI (2) SI4062916T1 (da)
SM (4) SMT202600114T1 (da)
TW (4) TW202322814A (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021024886A2 (pt) * 2019-06-11 2022-01-25 Amicus Therapeutics Inc Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WO2021026447A1 (en) * 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP2009537149A (ja) * 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US20140219986A1 (en) * 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
AU2017298376A1 (en) 2016-07-19 2019-03-07 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naive and ERT-experienced patients
KR20220116305A (ko) 2017-05-30 2022-08-22 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
WO2019017938A1 (en) * 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES

Also Published As

Publication number Publication date
FI4327869T3 (fi) 2026-03-09
LT4062916T (lt) 2025-01-10
TW202140000A (zh) 2021-11-01
EP4062916A1 (en) 2022-09-28
HRP20260346T1 (hr) 2026-04-24
FI4324522T3 (fi) 2026-03-09
FI3630114T3 (fi) 2024-01-30
RS67849B1 (sr) 2026-03-31
EP4327869A3 (en) 2024-05-22
EP4245366A9 (en) 2023-12-06
TWI775453B (zh) 2022-08-21
PL3630114T3 (pl) 2024-03-25
ES3065434T3 (en) 2026-05-06
TWI894750B (zh) 2025-08-21
CN111278438A (zh) 2020-06-12
EP4324522A3 (en) 2024-05-22
ES3052647T3 (en) 2026-01-12
HUE065615T2 (hu) 2024-06-28
RS66376B1 (sr) 2025-02-28
DK4062916T3 (da) 2025-01-13
EP3630114A1 (en) 2020-04-08
HRP20260335T1 (hr) 2026-04-10
DK3630114T3 (da) 2024-01-29
PT4062916T (pt) 2025-01-13
LT3630114T (lt) 2024-02-12
ES2970419T3 (es) 2024-05-28
LT4327869T (lt) 2026-03-25
DK4327869T3 (da) 2026-03-16
PT4327869T (pt) 2026-03-12
PL4327869T3 (pl) 2026-04-27
TW202440104A (zh) 2024-10-16
RS67861B1 (sr) 2026-04-30
CN120732857A (zh) 2025-10-03
SMT202600114T1 (it) 2026-05-12
SMT202500016T1 (it) 2025-03-12
SMT202400037T1 (it) 2024-03-13
EP4327868A2 (en) 2024-02-28
FI4062916T3 (fi) 2025-01-10
ES3002433T3 (en) 2025-03-06
EP4324522B1 (en) 2025-12-10
HUE069837T2 (hu) 2025-04-28
TW202322814A (zh) 2023-06-16
CN117357524A (zh) 2024-01-09
SI4062916T1 (sl) 2025-04-30
PT4324522T (pt) 2026-03-13
EP4062916B1 (en) 2024-10-09
HRP20241738T1 (hr) 2025-02-28
EP4324522A2 (en) 2024-02-21
PL4062916T3 (pl) 2025-03-17
SMT202600113T1 (it) 2026-05-12
TWI795408B (zh) 2023-03-11
EP4635496A1 (en) 2025-10-22
ES3065413T3 (en) 2026-05-06
PL4324522T3 (pl) 2026-04-27
EP4245366A2 (en) 2023-09-20
EP3630114B9 (en) 2026-05-20
SI3630114T1 (sl) 2024-03-29
EP4374918A3 (en) 2024-08-14
EP4245366A3 (en) 2023-11-29
EP4327869B1 (en) 2025-12-10
EP3630114B1 (en) 2023-11-01
RS65230B1 (sr) 2024-03-29
PT3630114T (pt) 2024-02-01
EP4062915A1 (en) 2022-09-28
CN119587544A (zh) 2025-03-11
LT4324522T (lt) 2026-03-25
TW201900165A (zh) 2019-01-01
EP4374918B1 (en) 2025-07-16
EP4374918A2 (en) 2024-05-29
HRP20240061T1 (hr) 2024-03-29
EP4327869A2 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
DK3448426T3 (da) Fremgangsmåder til behandling af patienter med familiær hyperkolesterolæmi
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3322722T3 (da) Midler, anvendelser og fremgangsmåder til behandling af synukleinopati
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
EP3256071C0 (en) AORTIC IMPLANT
IL270956A (en) Methods of treating fabry patients having renal impairment
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
PL3512642T3 (pl) Rozwiązanie bezmłotkowe
DK3507408T3 (da) Fremgangsmåde til fremstilling af nonwoven
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3513821T3 (da) Materiale til rensning af blod
IL260414B (en) Automatic deskew using design files or inspection images
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
EP3687670C0 (en) ARTIFICIAL KIDNEY DEVICE WITHOUT DIALYSATE
HUE053557T2 (hu) Eljárások akut vesekárosodás kezelésére
DK3334693T3 (da) Kontinuerlig fremgangsmåde og system til behandlingen af spildevand
DK3661510T3 (da) Fremgangsmåder til behandling af adfærdsændringer
DK3448340T3 (da) Applikationshjælpemiddel til behandling af sår
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3352735T3 (da) Olanzapinformuleringer med langvarig frigivelse